Your browser doesn't support javascript.
loading
Liver MRI and clinical findings to predict response after drug eluting bead transarterial chemoembolization in hepatocellular carcinoma.
Lee, Jeong Yeop; Lee, Byung Chan; Kim, Hyoung Ook; Heo, Suk Hee; Shin, Sang Soo; Jeong, Yong Yeon.
Afiliación
  • Lee JY; Department of Radiology, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun, 58128, Korea.
  • Lee BC; Department of Radiology, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun, 58128, Korea.
  • Kim HO; Department of Radiology, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469, Korea.
  • Heo SH; Department of Radiology, Chonnam National University Hwasun Hospital, 322 Seoyang-ro, Hwasun, 58128, Korea.
  • Shin SS; Department of Radiology, Chonnam National University Medical School, 42 Jebong-ro, Dong-gu, Gwangju, 61469, Korea.
  • Jeong YY; Department of Radiology, Chonnam National University Hospital, 42 Jebong-ro, Dong-gu, Gwangju, 61469, Korea.
Sci Rep ; 11(1): 24076, 2021 12 15.
Article en En | MEDLINE | ID: mdl-34911966
To identify the gadoxetic acid (GA)-enhanced magnetic resonance imaging (MRI) and laboratory findings that enable prediction of treatment response and disease-free survival (DFS) after the first session of drug eluting bead transarterial chemoembolization (DEB-TACE) in patients with hepatocellular carcinoma (HCC). A total of 55 patients who underwent GA-enhanced MRI and DEB-TACE from January 2014 to December 2018 were included. All MRI features were reviewed by two radiologists. Treatment response was evaluated according to the modified Response Evaluation Criteria in Solid Tumors. Univariate and multivariate logistic regression analyses were used to determine predictive factors of treatment response and DFS, respectively. A total of 27 patients (49.1%) achieved complete response (CR) after one session of treatment. There were no significant differences between the two groups in terms of clinical and laboratory characteristics. Heterogeneous signal intensity in the hepatobiliary phase (HBP) was the only independent predictor of non-CR (odds ratio, 4.807; p = 0.048). Recurrent HCC was detected in 19 patients (70.4%) after CR. In the multivariate analysis, elevated serum alpha-fetoprotein (AFP) level (≥ 30 ng/mL) was the only significant parameter associated with DFS (hazard ratio, 2.916; p = 0.040). This preliminary study demonstrated that heterogeneous signal intensity in the HBP and high serum AFP were useful predictive factors for poor treatment response and short DFS after DEB-TACE, respectively.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Imagen por Resonancia Magnética / Quimioembolización Terapéutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Imagen por Resonancia Magnética / Quimioembolización Terapéutica / Carcinoma Hepatocelular / Neoplasias Hepáticas Tipo de estudio: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Sci Rep Año: 2021 Tipo del documento: Article Pais de publicación: Reino Unido